Randomized controlled trials have shown a reduction in platelet alloimmunization and
refractoriness in patients with acute leukemia (AL) with the use of poststorage leukoreduction of …

Promising efficacy results of chimeric antigen receptor (CAR) T-cell therapy have been tempered
by safety considerations. Our objective was to comprehensively summarize the efficacy …

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant
cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We …

The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic
leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. …

For adults with Philadelphia chromosome‐negative (Ph−) acute lymphoblastic leukemia (ALL)
in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is …

Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic
leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have …

Pneumocystis jiroveci pneumonia (PJP) is associated with high morbidity and mortality after
hematopoietic stem cell transplantation (HSCT). Little is known about PJP infections after …

Timely diagnosis and care are major determinants of the outcome in acute promyelocytic
leukaemia ( APL ), a malignancy whose incidence may be increasing. The C anadian C ancer …

Elesclomol is a novel, injectable, small molecule chemotherapeutic agent that has demonstrated
preclinical efficacy in AML.[1, 2] Mechanistically, elesclomol binds copper (Cu) in the …

Background: Current chemotherapy regimens in children with ALL produce disease-free
survival (DFS) rates of greater than 80%. In contrast, adults with ALL have a much poorer …